Abstract Library

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#3209 Irinotecan and oxaliplatin based regimens of second-line treatment in gastrointestinal neuroendocrine carcinoma (GI-NEC) patients: A retrospective study

Introduction: Determination of second line treatment in metastatic gastrointestinal neuroendocrine carcinoma (GI-NEC) remains in controversy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhang J, Li J, Lu M, Shen L,

Keywords: gastrointestinal neuroendocrine carcinoma, second-line treatment, survival analysis, overall response rate,

#3167 Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)

Introduction: Owing to their low incidence, little evidence is available on the proper treatment of Neuroendocrine Carcinomas (NECs), a subgroup of tumors with scarce prognosis. Platinum plus Etoposide have been validated as first-line therapy since the 1991, while there is no consensus regarding further-lines treatment. Irinotecan (IRI)-based chemotherapy have shown promising results in second-line setting but data on safety are poor.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bardasi C

Authors: Bardasi C, Spallanzani A, Luppi G, Bertolini F, Fontana A,

Keywords: neuroendocrine carcinoma, Irinotecan, safety, second-line treatment, chemotherapy, NEC, adverse events,

#2864 Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,

Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,